FOR IMMEDIATE RELEASE
n
[City, State] – [Date, e.g., July 24, 2026] – Arrowhead Pharmaceuticals has announced groundbreaking top-line results from its pivotal global Phase III SHASTA-3 and SHASTA-4 clinical trials, demonstrating that plozasiran, an investigational RNA interference (RNAi) therapeutic, met its primary and all prespecified secondary endpoints in patients suffering from severe hypertriglyceridaemia (sHTG). The robust data indicates a significant reduction in triglyceride levels and, crucially, a statistically significant decrease in acute pancreatitis events, heralding a potential paradigm shift in the management of this high-risk metabolic condition.
n
The news marks a critical juncture for the pharmaceutical industry and, more importantly, offers a beacon of hope for millions worldwide grappling with the debilitating effects of sHTG and its life-threatening complications. With an impressive safety profile consistent with prior research, plozasiran stands poised to redefine treatment standards, potentially moving from a reactive management approach to a proactive, preventative strategy for acute pancreatitis in this vulnerable patient population.
n
Executive Summary: A New Era for Severe Hypertriglyceridaemia Treatment
n
Arrowhead Pharmaceuticals has unveiled overwhelmingly positive results from its Phase III SHASTA-3 and SHASTA-4 trials, evaluating plozasiran in patients with severe hypertriglyceridaemia (sHTG). The studies, designed as placebo-controlled, double-blind investigations, successfully achieved their primary objective of reducing triglyceride levels. Beyond this, plozasiran demonstrated a profound and statistically significant reduction in acute pancreatitis events, a severe and often recurrent complication of sHTG.
n
Patients receiving a 25 mg subcutaneous injection of plozasiran every three months exhibited median triglyceride reductions of 79% and 81% in SHASTA-3 and SHASTA-4, respectively, after 12 months, in stark contrast to approximately 27% in the placebo groups. Furthermore, a pooled analysis revealed a significant decrease in both the rate and total incidence of acute pancreatitis. Notably, for patients with very high triglyceride levels (over 880mg/dL) and a history of acute pancreatitis, plozasiran achieved a remarkable 100% reduction in events. The safety and tolerability profile remained consistent with previous findings, with no new concerns arising. These compelling results pave the way for Arrowhead Pharmaceuticals to pursue marketing authorization, beginning with a supplemental new drug application (sNDA) in the US later this year, promising a transformative therapeutic option for a patient population with significant unmet medical needs.
n
Main Facts: A New Horizon for sHTG Patients
n
The announcement from Arrowhead Pharmaceuticals represents a monumental stride forward in the battle against severe hypertriglyceridaemia, a condition characterized by dangerously high levels of triglycerides in the blood, often leading to severe health complications, most notably acute pancreatitis. The success of plozasiran in the global Phase III SHASTA-3 and SHASTA-4 clinical trials signals the advent of a potentially game-changing therapeutic option.
n
Landmark Phase III Trials Achieve Primary and Secondary Endpoints
n
The SHASTA-3 and SHASTA-4 studies were meticulously designed as multi-centre, placebo-controlled, double-blind trials, representing the gold standard in clinical research. This rigorous methodology ensures that neither the participants nor the researchers involved in administering the treatment or assessing outcomes knew who was receiving the active drug versus the placebo, thereby minimizing bias and bolstering the reliability of the findings. The primary objective, a significant reduction in triglyceride levels compared to placebo, was definitively met across both trials.
n
However, the impact of plozasiran extends far beyond simple lipid reduction. The trials also successfully achieved all prespecified secondary endpoints, a testament to the drug’s broad therapeutic potential. Among these, the most clinically impactful finding was a statistically significant decrease in acute pancreatitis events. This outcome is particularly crucial given that acute pancreatitis is a severe, painful, and potentially fatal complication that frequently recurs in patients with sHTG. The ability of plozasiran to not only lower triglyceride levels but also directly mitigate this life-threatening risk underscores its profound clinical value.
n
The treatment regimen involved participants receiving a 25 mg dose of plozasiran via subcutaneous injection every three months. This convenient dosing schedule, requiring only four injections per year, could significantly enhance patient adherence and long-term management compared to daily oral medications. The simplicity of administration further strengthens plozasiran’s appeal as a practical and effective therapeutic intervention for a chronic condition requiring sustained management.
n
Plozasiran: A Novel RNAi Therapeutic Targeting Lipid Metabolism
n
Plozasiran is an investigational drug built upon the innovative platform of RNA interference (RNAi). This cutting-edge technology harnesses the body’s natural cellular processes to "silence" specific genes responsible for disease. In the context of hypertriglyceridaemia, plozasiran is designed to target genes involved in the synthesis or regulation of triglycerides, effectively reducing their production or enhancing their clearance from the bloodstream.
n
Unlike traditional small-molecule drugs that typically inhibit protein function, RNAi therapeutics work upstream by preventing the creation of disease-causing proteins in the first place. This precision-guided approach offers several advantages, including high specificity, potentially fewer off-target effects, and the ability to achieve sustained therapeutic effects with less frequent dosing. Plozasiran’s mechanism represents a sophisticated biological intervention, promising a highly effective and targeted approach to managing severe lipid disorders. Its success further validates the growing prominence of RNAi therapeutics as a powerful new class of medicines capable of addressing previously intractable diseases.
n
Chronology of Discovery and Development
n
The journey of any novel therapeutic from concept to clinical success is often long and arduous, marked by rigorous scientific investigation and incremental progress. Plozasiran’s path to Phase III success is no exception, reflecting years of dedicated research and development.
n
From Preclinical Promise to Pivotal Phase III
n
The genesis of plozasiran began in preclinical laboratories, where initial studies explored its molecular mechanism and therapeutic potential in animal models of hypertriglyceridaemia. These early investigations demonstrated promising triglyceride-lowering effects and a favourable safety profile, providing the foundational data necessary to advance to human trials.
n
Following successful preclinical validation, plozasiran entered Phase I clinical trials, primarily focused on assessing its safety, tolerability, and pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes the drug) in healthy volunteers. These initial human studies confirmed the drug’s safety and provided crucial insights into appropriate dosing strategies. The encouraging results from Phase I paved the way for Phase II trials, which began to evaluate the drug’s efficacy in a larger cohort of sHTG patients, while continuing to monitor safety. The Phase II data further solidified plozasiran’s potential, showing dose-dependent reductions in triglycerides and reinforcing its safety profile, thereby justifying progression to the pivotal Phase III program.
n
The SHASTA-3 and SHASTA-4 trials, as the culmination of this extensive development pathway, were designed to definitively prove plozasiran’s efficacy and safety in a large, diverse patient population, meeting the stringent requirements for regulatory approval. The successful outcome of these trials is a testament to the methodical and rigorous approach taken by Arrowhead Pharmaceuticals throughout the drug’s development.
n
The Rigour of Placebo-Controlled, Double-Blind Studies
n
The design of the SHASTA-3 and SHASTA-4 trials as placebo-controlled, double-blind studies is paramount to the credibility and scientific robustness of their findings. In a placebo-controlled trial, one group of participants receives the active drug (plozasiran), while another group receives an inert substance (placebo) that looks identical to the active drug. This allows researchers to distinguish the true effects of the drug from the "placebo effect," which is the psychological or physiological benefit a patient might experience simply from believing they are receiving treatment.
n
The "double-blind" aspect adds another layer of stringency. Neither the patients nor the researchers administering the treatment or collecting data are aware of which participants are receiving the active drug and which are receiving the placebo. This blinding prevents conscious or unconscious bias from influencing the study outcomes. For instance, if researchers knew which patients were on the active drug, they might inadvertently pay more attention to their improvements or interpret symptoms differently. Similarly, patients who know they are receiving an experimental drug might report more positive outcomes. By eliminating these biases, double-blind, placebo-controlled trials provide the most objective and reliable evidence of a drug’s efficacy and safety. The fact that plozasiran met its endpoints under such rigorous conditions underscores the strength and validity of its therapeutic effects.
n
Supporting Data: Unpacking the Efficacy and Safety Profile
n
The data presented by Arrowhead Pharmaceuticals from the SHASTA-3 and SHASTA-4 trials is not merely statistically significant; it represents a profound clinical impact for patients suffering from severe hypertriglyceridaemia. The magnitude of triglyceride reduction, coupled with the dramatic decrease in acute pancreatitis events, paints a compelling picture of plozasiran’s potential.
n
Dramatic Reductions in Triglyceride Levels
n
After 12 months of treatment, the SHASTA-3 and SHASTA-4 trials reported median triglyceride reductions of 79% and 81%, respectively, in patients receiving plozasiran. This stands in stark contrast to the placebo group, which saw reductions of only around 27%. These figures are highly significant. For patients whose triglyceride levels often soar into the thousands of milligrams per deciliter (mg/dL), even exceeding 2000 mg/dL in severe cases, a nearly 80% reduction can bring these levels down to a much safer range, dramatically reducing the risk of complications.
n
For context, normal triglyceride levels are typically below 150 mg/dL, while severe hypertriglyceridaemia is defined by levels exceeding 500 mg/dL, with very severe cases often surpassing 1000 mg/dL. Bringing a patient’s triglyceride level from, for example, 1500 mg/dL down to approximately 300 mg/dL or less with plozasiran could mean the difference between constant fear of pancreatitis and a significantly improved quality of life with reduced health risks. This level of efficacy is a substantial improvement over many existing lipid-lowering therapies and represents a significant step forward in achieving optimal lipid management for sHTG patients.
n
Preventing Acute Pancreatitis: A Game-Changer
While triglyceride reduction is critical, the prevention of acute pancreatitis is arguably the most impactful finding from these trials. Acute pancreatitis is an excruciatingly painful and dangerous inflammation of the pancreas, often triggered by very high triglyceride levels. It can lead to prolonged hospital stays, organ failure, and even death. Recurrent episodes can severely diminish a patient’s quality of life and carry significant morbidity and mortality.
A pre-planned pooled analysis from both SHASTA studies revealed a statistically significant reduction in the rate of acute pancreatitis among those treated with plozasiran. The reported p-values of less than 0.0221 for event rates and less than 0.0077 for total incidence rates underscore the robustness of this finding. In statistical terms, a p-value below 0.05 is generally considered significant, indicating a very low probability that the observed effect occurred by chance. These low p-values thus provide strong evidence that plozasiran directly contributes to the prevention of pancreatitis.
The clinical significance of these reductions is even more striking when examined in specific patient populations:
- Broader sHTG Population (Triglycerides > 500mg/dL): In this general population of sHTG patients, plozasiran treatment was associated with a remarkable 78% reduction in cumulative acute pancreatitis events compared to placebo. This suggests that plozasiran can provide substantial protection against this feared complication for a wide range of sHTG patients.
- High-Risk Subset (Triglycerides > 880mg/dL and History of Acute Pancreatitis): For the most vulnerable patients – those with extremely high triglyceride levels (over 880mg/dL) and a previous history of acute pancreatitis (making them highly susceptible to recurrence) – SHASTA-3 and SHASTA-4 identified an astounding 100% reduction in events for those receiving plozasiran. This finding is truly exceptional. It implies that plozasiran could completely eliminate the risk of recurrent pancreatitis in a patient group for whom this risk is exceptionally high, offering an unprecedented level of protection and potentially transforming their prognosis and quality of life. This outcome alone positions plozasiran as a potentially life-saving medication for these high-risk individuals.
Consistent Safety and Tolerability
The safety and tolerability profile of plozasiran in the SHASTA-3 and SHASTA-4 studies was reported as consistent with previous research, a critical factor for any drug intended for long-term use in a chronic condition. The observed treatment-emergent adverse events aligned with earlier findings, and crucially, no new safety issues were detected. This consistency across trial phases and larger patient cohorts provides reassurance regarding the drug’s predictable safety profile.
Furthermore, the studies found no statistically significant differences between plozasiran and placebo in mean liver fat content or adverse changes in liver enzymes. Liver health is a common concern with lipid-lowering therapies, and the absence of negative impact on the liver is a significant positive indicator. There were also no cases of hypersensitivity reactions (allergic responses) or thrombocytopenia (low platelet count), which can sometimes be side effects of certain medications. This robust safety profile, combined with its profound efficacy, strengthens plozasiran’s position as a highly promising therapeutic candidate.
Official Responses and Expert Commentary
The successful outcome of the SHASTA trials has generated considerable excitement within Arrowhead Pharmaceuticals and is expected to resonate widely across the medical and scientific communities.
Arrowhead Pharmaceuticals on the Brink of a New Era
James Hamilton, Arrowhead’s chief medical officer and head of R&D, expressed profound optimism regarding the trial results. "These findings highlight the potential of plozasiran as a promising therapy for patients across the spectrum of sHTG," Hamilton stated. His comments underscore the drug’s versatility and its ability to address varying degrees of severe hypertriglyceridaemia, from moderate to very high-risk cases. The leadership at Arrowhead Pharmaceuticals views these results not just as a scientific achievement, but as a pivotal moment that could reshape the company’s trajectory and its contribution to global health. The company’s strategic focus on RNAi therapeutics is being validated by these robust clinical outcomes, positioning Arrowhead as a frontrunner in this innovative field.
Beyond Hamilton’s direct quote, the implications for Arrowhead are substantial. The successful completion of Phase III trials with such compelling data significantly de-risks the drug’s development and substantially increases its likelihood of regulatory approval. This success can attract further investment, potentially accelerate other pipeline programs, and solidify Arrowhead’s reputation as a leader in developing novel, targeted therapies for challenging diseases.
A Beacon of Hope for a Neglected Patient Population
Severe hypertriglyceridaemia often goes undiagnosed or undertreated until a patient experiences a severe episode of acute pancreatitis. The current treatment landscape for sHTG is often suboptimal, relying on dietary modifications, exercise, and a limited array of medications that may not achieve sufficient triglyceride reduction or consistently prevent pancreatitis. Patients with sHTG often face a constant threat to their health, enduring chronic anxiety about potential episodes of pancreatitis, which can necessitate emergency hospitalizations, intense pain management, and lengthy recovery periods.
For clinicians, managing sHTG has been a perpetual challenge, balancing the need for aggressive lipid lowering with the limitations of available therapies and the complex adherence issues associated with lifestyle changes. Plozasiran’s ability to offer profound triglyceride reduction and, crucially, robust pancreatitis prevention with a convenient quarterly dosing schedule, addresses major unmet needs. Experts in cardiology and endocrinology are likely to welcome these results with enthusiasm, recognizing the profound impact such a therapy could have on patient outcomes and the overall burden of disease. Patient advocacy groups are also expected to champion plozasiran, as it promises to alleviate significant suffering and improve the quality of life for a population that has long awaited more effective treatment options.
Implications for Patients, Clinicians, and the Pharmaceutical Landscape
The positive results from the SHASTA trials have far-reaching implications, promising to transform clinical practice, influence healthcare policy, and further validate the power of RNAi technology.
Transforming the Treatment Paradigm for sHTG
Plozasiran has the potential to fundamentally alter the approach to managing severe hypertriglyceridaemia. Currently, treatment often involves a combination of fibrates, omega-3 fatty acids, and dietary restrictions, with varying degrees of success. For many, achieving target triglyceride levels and preventing pancreatitis remains elusive. Plozasiran offers a highly effective, targeted, and convenient option that could become a cornerstone therapy.
Clinicians may soon have the ability to proactively manage sHTG with a therapy that not only reduces a key biomarker (triglycerides) but also directly prevents its most devastating complication. This shift from reactive management to preventative care could significantly reduce hospitalizations, emergency room visits, and the overall healthcare burden associated with sHTG. For patients, this means a drastically reduced risk of acute pancreatitis, less pain, fewer interruptions to their daily lives, and ultimately, a better quality of life and improved long-term prognosis. The quarterly subcutaneous injection could also enhance adherence compared to daily oral regimens, leading to more consistent therapeutic effects and better patient outcomes.
Regulatory Pathway and Market Access
Arrowhead Pharmaceuticals has outlined a clear pathway to bring plozasiran to patients. The company intends to pursue marketing authorization in multiple countries, with the immediate focus on filing a supplemental new drug application (sNDA) in the US before the end of this year. An sNDA is typically filed for a new indication, dosage form, or patient population for an already approved drug, but in this context, it implies a comprehensive submission for a novel drug.
The US Food and Drug Administration (FDA) will conduct a thorough review of the extensive data from the SHASTA trials, assessing the drug’s efficacy, safety, and benefit-risk profile. Given the compelling results, particularly the prevention of acute pancreatitis in a high-risk population, plozasiran may receive priority review status, potentially accelerating its approval timeline. Following a potential US approval, Arrowhead is expected to pursue similar regulatory submissions in Europe, Asia, and other key markets. The successful navigation of these regulatory processes will be crucial for widespread patient access and commercial success. The timeline from sNDA submission to potential approval can range from six months to over a year, meaning plozasiran could be available to patients as early as late 2027 or early 2028.
Broader Impact on RNAi Therapeutics
The success of plozasiran in such a critical Phase III program further solidifies the burgeoning field of RNA interference therapeutics. Pioneering drugs like patisiran (for hATTR amyloidosis) and inclisiran (for hypercholesterolemia) have already demonstrated the power of RNAi to treat genetic and chronic diseases. Plozasiran’s success in sHTG adds another significant feather to the cap of this technology, showcasing its versatility and efficacy across different metabolic pathways.
This continued validation will likely spur further investment and research into RNAi drugs for a wider array of conditions, from rare genetic disorders to common chronic diseases. The precision, potency, and infrequent dosing schedules offered by RNAi therapeutics represent a significant evolution in drug development, promising a new generation of medicines that can effectively target the root causes of disease with fewer side effects. Arrowhead Pharmaceuticals, with its robust RNAi pipeline, is strategically positioned to be a key player in this evolving landscape.
Conclusion: A Milestone Achievement
The top-line results from the SHASTA-3 and SHASTA-4 trials represent a significant milestone not only for Arrowhead Pharmaceuticals but for the entire medical community dedicated to improving the lives of patients with severe hypertriglyceridaemia. Plozasiran’s demonstrated ability to achieve dramatic reductions in triglyceride levels and, critically, to significantly prevent acute pancreatitis events, marks a pivotal moment in the treatment of this challenging condition.
As Arrowhead Pharmaceuticals prepares to present detailed results at the European Society of Cardiology Congress on August 30, 2026, and subsequently pursue marketing authorization, the promise of plozasiran shines brightly. This innovative RNAi therapeutic holds the potential to transform patient care, offering a new standard of efficacy and safety for a population that has long endured significant health risks and limited therapeutic options. The future for severe hypertriglyceridaemia patients, thanks to plozasiran, appears considerably brighter.
